Developing innovative treatments for KRAS-driven cancers

Silexion Therapeutics Corp. (NASDAQ: SLXN) is a clinical-stage biopharmaceutical company developing RNA interference (RNAi) treatments for KRAS-driven cancers, including pancreatic cancer. Its lead candidate, SIL204, is being investigated in a Phase 2/3 clinical program for locally advanced pancreatic cancer.

Company Profile

Silexion Therapeutics combines cutting-edge science, advanced technologies, and a passion for innovation to address the significant unmet medical needs in pancreatic cancer treatment.

Silexion is currently investigating SIL204, a pan-KRAS RNA silencing therapy, in a Phase 2/3 clinical program for locally advanced pancreatic cancer.

Core Technologies

RNA interference harnesses natural biological mechanisms to silence cancer-causing genes before proteins are produced.

Silexion's delivery systems target high LDL receptor expressing tumors and micrometastases.

SIL204

SIL204 is Silexion's lead candidate, combining siRNA and PLG microparticle technology for the treatment of solid tumors.

Latest Press Releases